STOCKHOLM - December 3, 2025 - The board of directors of Inify Laboratories AB
("Inify" or the "Company") announces its intention to postpone the last date of
payment in the Company's proposed share issues announced on November 12, 2025,
(the "Private Placement" and the "Repair Issue" respectively). The final payment
date is intended to be postponed to March 25, 2026, providing shareholders with
additional time to procure the necessary funds to participate in the Private
Placement and the Repair Issue.

The postponement of the last date of payment will also affect the expected final
date of delivery of new shares in the Private Placement and the Repair Issue.
The new shares in the Private Placement and the Repair Issue are expected to be
fully delivered to the participants in the Private Placement and Repair Issue by
March 30, 2026. Further, all the new shares allocated in the Private Placement
and the Repair Issue are expected to be tradable on Euronext Growth Oslo by
March 30, 2026.

For further information, please contact CEO, Fredrik Palm,
[email protected],or visit
https://www.inify.com (https://protect.checkpoint.com/v2/r02/___https://www.inif
y
.com___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3OjFj
M
TM6YjE3M2Q4MTI2YmQxZjEyYzJmYWVhMzdlYWFiMTNiZGVlMjdkZjA1MjdlMTNjN2JlOTMyYmNkZDZmN
z
ViNjhhMjpwOlQ6VA)

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo(https://live.euronext.com/en/product/equities/SE0017486103
-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwt
i
zhydjvznynjxdXJ556a9b*~*658
-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc
3
NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZl
O
TE5NmJhMjpwOlQ6VA)) under the ticker
INIFY.(https://live.euronext.com/en/product/equities/SE0017486103
-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwt
i
zhydjvznynjxdXJ556a9b*~*658
-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc
3
NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZl
O
TE5NmJhMjpwOlQ6VA))

###

This information is subject to the disclosure requirements pursuant to section 5
-12 the Norwegian Securities Trading Act.

###

Important information

The release, announcement or distribution of this press release may, in certain
jurisdictions, be subject to restrictions. The recipients of this press release
in jurisdictions where this press release has been published or distributed
shall inform themselves of and follow such restrictions. The recipient of this
press release is responsible for using this press release, and the information
contained herein, in accordance with applicable rules in each jurisdiction. The
information in this press release does not contain or constitute an offer to
acquire, subscribe or otherwise trade in shares, subscription rights or other
securities in the Company in any jurisdiction.

This press release does not identify or suggest, or purport to identify or
suggest, the risks (direct or indirect) that may be associated with an
investment in new shares. Any investment decision in connection with the Private
Placement and Repair Issue must be made on the basis of all publicly available
information relating to the Company and the Company's shares. Such information
has not been independently verified by SB1 Markets. The information contained in
this announcement is for background purposes only and does not purport to be
full or complete. No reliance may be placed for any purpose on the information
contained in this announcement or its accuracy or completeness. SB1 Markets is
acting for the Company in connection with the transaction and no one else and
will not be responsible to anyone other than the Company for providing the
protections afforded to its clients nor for giving advice in relation to the
transaction or any other matter referred to herein.

This press release does not constitute a recommendation concerning any
investor's option with respect to the Private Placement and Repair Issue. Each
investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data described in
this announcement and publicly available information. The price and value of
securities can go down as well as up. Past performance is not a guide to future
performance.

The information contained in this press release is not intended for, and must
not be accessed by, or distributed or disseminated, directly or indirectly, in
whole or in part, to persons resident or physically present in the United States
of America (including its territories and possessions, any state of the United
States and the District of Columbia) (the "United States"), Australia, Canada,
Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any
other jurisdiction where such action is wholly or partially subject to legal
restrictions, or would require additional prospectuses, registration or other
measures than those required by Swedish law. The information in the press
release does not constitute any offer regarding subscription rights, paid
subscribed shares or shares in the Company ("Securities") to any person in said
jurisdictions. The information in the press release may not be forwarded or
reproduced in such a manner that contravenes such restrictions or gives cause to
such requirements.

No securities have been or will be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities legislation of
any state or other jurisdiction in the United States and may not be offered,
subscribed for, exercised, used, pledged, sold, resold, granted, delivered or
otherwise transferred, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a transaction not subject
to, the registration requirements under the Securities Act and in compliance
with the securities legislation in the relevant state or any other jurisdiction
of the United States.

Within the European Economic Area ("EEA"), no public offering of Securities is
made in other countries than Sweden or Norway. In other member states of the EU,
such an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other
member states of the EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in accordance
with an applicable exemption in the Prospectus Regulation and/or in accordance
with an applicable exemption under a relevant national implementation measure.

In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, "qualified investors" who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order")